Michael Schweizer, MD, discusses the results of the HERO trial in prostate cancer.
Michael Schweizer, MD
Advertisement
Articles by Michael Schweizer, MD
Michael Schweizer, MD, discusses the rationale for the phase 3 CARD trial in metastatic castration-resistant prostate cancer.
Michael Schweizer, MD, discusses the role of olaparib in patients with non–BRCA-mutant metastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Dr. Schweizer on the Rationale for the CARD Trial in mCRPCPublished: December 21st 2020 | Updated:
Dr. Schweizer on the Role of Olaparib in Non–BRCA-Mutant mCRPCPublished: December 7th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5